Impact of gut microbiome on immunotherapy resistance in hepatocellular carcinoma: a review article

Abstract

This article reviews the interactions between gut microbiota and cancer immunotherapies and discusses microbiota-based patient stratification strategies such as the prediction of response and the early recognition of toxic events. Additionally, it explores the emerging potential of microbiotherapy to enhance anti-neoplastic efficacy and alleviate toxicity, with the ultimate goal of developing personalized treatment regimens for patients with hepatocellular carcinoma (HCC).

Keywords

Hepatocellular carcinoma / HCC / immunotherapy / microbiota / microbiome

References

[1] El-Serag HB.Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.Gastroenterology2007;132:2557-76

[2] Bruix J,Meinhardt G,De Sanctis Y.Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies.J Hepatol2017;67:999-1008

[3] ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology2016;64:138-49

[4] Huang Y,Liu J,Zeng Y.The breakthroughs in cancer immune checkpoint based therapy: a review of development in immune checkpoint study and its application.Comb Chem High Throughput Screen2017;20:430-39

[5] Lee JB,Ha SJ.Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy.Immune Netw2022;22:e2 PMCID:PMC8901707

[6] Nguyen LT.Clinical blockade of PD1 and LAG3--potential mechanisms of action.Nat Rev Immunol2015;15:45-56

[7] El-Khoueiry AB,Yau T.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet2017;389:2492-502 PMCID:PMC7539326

[8] Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894-905.

[9] Asrani SK,Eaton J. Burden of liver diseases in the world. 2019;70:151-71. Available from: https://www.journal-of-hepatology.eu/article/S0168-8278(18)32388-2/abstract. [Last accessed on 7 Nov 2024].

[10] Fu J.Precision diagnosis and treatment of liver cancer in China.Cancer Lett2018;412:283-8

[11] Shi Z,Song W,Li Z.Emerging roles of the gut microbiota in cancer immunotherapy.Front Immunol2023;14:1139821 PMCID:PMC9992551

[12] Ragonnaud E.Gut microbiota as the key controllers of “healthy” aging of elderly people.Immun Ageing2021;1:2 PMCID:PMC7784378

[13] Badal VD,Murray ER.The gut microbiome, aging, and longevity: a systematic review.Nutrients2020;12:3759 PMCID:PMC7762384

[14] Claesson MJ,O'Sullivan O.Composition, variability, and temporal stability of the intestinal microbiota of the elderly.Proc Natl Acad Sci USA2011;108 Suppl 1:4586-91 PMCID:PMC3063589

[15] Ni Y,Xu Y.The role of gut microbiota-bile acids axis in the progression of non-alcoholic fatty liver disease.Front Microbiol2022;13:908011 PMCID:PMC9271914

[16] Renz H,Brandtzaeg P,Autenrieth IB.Gene-environment interactions in chronic inflammatory disease.Nat Immunol2011;12:273-7

[17] Ursell LK,Rideout JR,Caporaso JG.The interpersonal and intrapersonal diversity of human-associated microbiota in key body sites.J Allergy Clin Immunol2012;129:1204-8 PMCID:PMC3342686

[18] Cani PD,Knauf C.Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice.Diabetes2008;57:1470-81

[19] Henao-Mejia J,Jin C.Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.Nature2012;482:179-85 PMCID:PMC3276682

[20] Paolella G,Pierri L,Di Stasi M.Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.World J Gastroenterol2014;20:15518-31 PMCID:PMC4229517

[21] Li R,Ye X.Human gut microbiome and liver diseases: from correlation to causation.Microorganisms2021;9:1017 PMCID:PMC8151257

[22] Ji Y,Sun L.The molecular and mechanistic insights based on gut-liver axis: nutritional target for non-alcoholic fatty liver disease (NAFLD) improvement.Int J Mol Sci2020;21:3066 PMCID:PMC7247681

[23] Vaziri F,Wan YY.Hepatocellular carcinoma immunotherapy: the impact of epigenetic drugs and the gut microbiome.Liver Res2020;4:191-8 PMCID:PMC7746137

[24] Matson V,Gajewski TF.Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy.Gastroenterology2021;160:600-13 PMCID:PMC8409239

[25] Gopalakrishnan V,Nezi L.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.Science2018;359:97-103

[26] Lu Y,Wang M.Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies.J Hematol Oncol2022;15:47 PMCID:PMC9052532

[27] Zhang SL,Zhang ZY.Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer.Theranostics2021;11:4155-70 PMCID:PMC7977465

[28] He Y,Li Y.Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8⁺ T cell immunity.Cell Metab2021;33:988-1000.e7

[29] Wan MLY.Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy.Hepatobiliary Surg Nutr2018;7:11-20 PMCID:PMC5835615

[30] Ponziani FR,Picca A.Gut dysbiosis and fecal calprotectin predict response to immune checkpoint inhibitors in patients with hepatocellular carcinoma.Hepatol Commun2022;6:1492-501 PMCID:PMC9134810

[31] Li L.Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors: a Chinese population-based study.Medicine2020;99:e21788 PMCID:PMC7489660

[32] Davar D,McCulloch JA.Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients.Science2021;371:595-602 PMCID:PMC8097968

[33] McQuade JL,Helmink BA.Modulating the microbiome to improve therapeutic response in cancer.Lancet Oncol2019;20:e77-91

[34] Pei B,Huang C.Bifidobacterium modulation of tumor immunotherapy and its mechanism.Cancer Immunol Immunother2024;73:94 PMCID:PMC10987355

[35] Park JS,Kasper DL.Microbiota-dependent regulation of costimulatory and coinhibitory pathways via innate immune sensors and implications for immunotherapy.Exp Mol Med2023;55:1913-21 PMCID:PMC10545783

[36] Gunjur A,Rozday T.A gut microbial signature for combination immune checkpoint blockade across cancer types.Nat Med2024;30:797-809 PMCID:PMC10957475

[37] Xue P,Zhou Y.The aryl hydrocarbon receptor and tumor immunity.Front Immunol2018;9:286 PMCID:PMC5816799

[38] Yu J,Shi L.Bifidobacterium longum promotes postoperative liver function recovery in patients with hepatocellular carcinoma.Cell Host Microbe2024;32:131-144.e6

[39] Roussel E,Tuech JJ.Influence of probiotics administration before liver resection in patients with liver disease: a randomized controlled trial.World J Surg2022;46:656-65

[40] Mao J,Long J.Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.J Immunother Cancer2021;9:e003334 PMCID:PMC8650503

[41] Russo E,Giudici F.Immunomodulation by probiotics and prebiotics in hepatocellular carcinoma.World J Hepatol2022;14:372-85 PMCID:PMC8891667

[42] Spanu D,Lai E.Hepatocellular carcinoma and microbiota: implications for clinical management and treatment.World J Hepatol2022;14:1319-32 PMCID:PMC9376771